Co-Authors
This is a "connection" page, showing publications co-authored by SAIRA KHADERI and HASHEM EL-SERAG.
Connection Strength
2.221
-
HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2024 Jun 19.
Score: 0.243
-
PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
Score: 0.242
-
Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. Gut. 2024 Feb 16.
Score: 0.238
-
Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
Score: 0.231
-
Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
Score: 0.225
-
Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
Score: 0.222
-
Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
Score: 0.222
-
A multidisciplinary approach to improving transition readiness in pediatric liver transplant recipients. Pediatr Transplant. 2021 03; 25(2):e13839.
Score: 0.188
-
Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
Score: 0.182
-
Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
Score: 0.169
-
Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology. 2024 07 01; 80(1):87-101.
Score: 0.059